MoonLake Immunotherapeutics
MLTX Nasdaq
SEC CIK 1821586
Follow MoonLake Immunotherapeutics
Weekly email: filings, results
Net income
−$79.5M
−14.1% vs same quarter last year
EPS, diluted
−$0.93
+15.5% vs same quarter last year
Operating cash flow
−$63.4M
−42.3% vs same quarter last year
Operating income
−$79.9M
−11.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$227.3M |
| FY24 | −$118.9M |
| FY23 | −$36M |
| FY22 | −$50M |
| FY21 | −$4.5M |
| FY20 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$196M |
| FY24 | −$117.1M |
| FY23 | −$43.1M |
| FY22 | −$55.9M |
| FY21 | - |
| FY20 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | $50 |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |